In the landscape of modern preventive medicine, the "cardiac risk score" has long served as a primary gatekeeper for patient health. For millions of adults, a routine visit to the primary care physician involves a calculation of age, cholesterol levels, blood pressure, and smoking status to determine their 10-year likelihood of a cardiovascular event. However, a groundbreaking study led by researchers at Mount Sinai, published on November 21 in the Journal of the American College of Cardiology: Advances, suggests that these standard tools may be providing a false sense of security for a significant portion of the population.
The study reports that commonly used cardiac screening methods—specifically the atherosclerotic cardiovascular disease (ASCVD) risk score and the newer PREVENT tool—fail to identify nearly half of the individuals who are at imminent risk of a heart attack. These findings represent a critical challenge to current clinical guidelines, suggesting that the medical community’s reliance on population-based risk calculators may be fundamentally misaligned with the reality of individual patient health.
The Architecture of Current Cardiac Risk Assessment
To understand the scope of the problem, one must first understand the current protocol. In routine clinical practice, physicians utilize the ASCVD risk score for adults aged 40 to 75 who have no documented history of heart disease. This tool synthesizes a patient’s demographic and physiological data—sex, race, blood pressure, cholesterol levels, diabetes status, and tobacco use—to assign a percentage probability of experiencing a heart attack or stroke within the next decade.
These scores act as a "triaging" mechanism. Patients who fall into the intermediate or high-risk categories are typically flagged for aggressive interventions, such as the prescription of statins or the scheduling of advanced diagnostic tests. Conversely, individuals who register as low or borderline risk—particularly those who report no classic symptoms like chest pain or shortness of breath—are often reassured that their heart health is stable, requiring no further immediate evaluation.
The newer PREVENT tool, designed to improve upon the ASCVD model, incorporates a broader set of variables to provide a more nuanced picture of cardiovascular risk. Yet, the Mount Sinai researchers found that even this advanced iteration failed to capture the true danger facing a majority of patients who ultimately experienced a cardiac event.
Chronology of the Investigation
The study was born out of a desire to reconcile the discrepancy between "predicted risk" and "actual outcomes." To investigate the accuracy of these screening tools, the research team conducted a rigorous, retrospective review of 474 patients under the age of 66. Each of these individuals had no known history of coronary artery disease but was treated for a first-time heart attack at either The Mount Sinai Hospital or Mount Sinai Morningside between January 2020 and July 2025.
The investigation proceeded in three distinct phases:
- Data Harvesting: Researchers compiled comprehensive medical dossiers for each participant, including demographics, clinical history, lipid profiles, and precise timelines regarding the onset of symptoms.
- Simulation of Pre-Event Clinical Care: The team then performed a "back-in-time" analysis. They calculated what the patient’s ASCVD and PREVENT risk scores would have been just 48 hours prior to their heart attack.
- Risk Categorization: Patients were sorted into four established risk buckets: low (under 5 percent), borderline (5–7.5 percent), intermediate (7.5–20 percent), and high (more than 20 percent).
The results provided a startling look at the limitations of current diagnostic gatekeeping.
Supporting Data: The Failure of the "Gatekeeper" Model
The statistical findings of the study are as sobering as they are clear. When the researchers applied the standard ASCVD guidelines to these patients two days before their cardiac events, they found that 45 percent of the patients would not have been recommended for preventive therapy or further diagnostic testing.
The performance of the newer PREVENT tool was even less accurate in this cohort, failing to identify 61 percent of the patients as candidates for preventive care.
Perhaps most concerning was the timing of symptoms. The study found that 60 percent of the patients experienced their first symptoms fewer than two days before their heart attack. This reinforces a dangerous reality: by the time a patient experiences the classic signs of heart disease—such as chest pain or shortness of breath—the underlying atherosclerosis is already significantly advanced. The diagnostic tools currently in use are effectively "blind" to the silent progression of plaque until the moment of crisis.
Official Responses and Clinical Perspectives
Dr. Amir Ahmadi, the study’s corresponding author and a Clinical Associate Professor of Medicine (Cardiology) at the Icahn School of Medicine at Mount Sinai, argues that these findings necessitate a paradigm shift in how cardiologists approach prevention.
"Our research shows that population-based risk tools often fail to reflect the true risk for many individual patients," Dr. Ahmadi stated. "If we had seen these patients just two days before their heart attack, nearly half would not have been recommended for further testing or preventive therapy guided by current risk estimate scores and guidelines."
Dr. Ahmadi suggests that the current reliance on risk scores and symptomatic self-reporting is "not optimal." He advocates for a transition toward direct imaging. "It may be time to fundamentally reconsider this model and move toward atherosclerosis imaging to identify the silent plaque—early atherosclerosis—before it has a chance to rupture," he noted.
First author Dr. Anna Mueller, an internal medicine resident at the Icahn School of Medicine at Mount Sinai, echoed this sentiment, emphasizing the danger of the "low-risk" label.
"When we look at heart attacks and trace them backwards, most heart attacks occur in patients in the low or intermediate risk groups," Dr. Mueller explained. "This study highlights that a lower risk score, along with not having classic heart attack symptoms, is no guarantee of safety on an individual level. Our study exposes a major flaw where tools effective for tracking large populations fall short when guiding individualized care."
Implications: A Call for a New Preventive Paradigm
The implications of the Mount Sinai study are vast, reaching into the heart of primary care practices across the globe. If current risk calculators are underestimating the danger for such a large segment of the population, it suggests that thousands of patients who believe they are "low risk" may actually be harboring significant, yet silent, coronary artery disease.
The Shift Toward Imaging
The study’s most significant recommendation is the potential integration of cardiovascular imaging—such as coronary artery calcium (CAC) scoring or CT angiography—into broader screening protocols. While current guidelines often reserve these tests for patients already deemed "intermediate risk," the Mount Sinai data suggests that such tests might need to be utilized earlier to detect silent plaque in patients who would otherwise be classified as "low risk" by traditional calculators.
Addressing the Symptom Gap
The fact that 60 percent of patients experienced symptoms less than 48 hours before their heart attack underscores the inadequacy of relying on patient-reported symptoms as an indicator for intervention. Preventive medicine must transition from a reactive model—where doctors wait for a patient to report distress—to a proactive model, where diagnostic technology is used to identify disease before the patient ever feels unwell.
The Need for Refined Tools
While the researchers acknowledge that more work is required, the study serves as a clarion call for the medical community to refine the variables within risk calculators. Population-based tools provide a statistical average, but they cannot replace the need for granular, patient-specific diagnostic data.
Conclusion: The Path Forward
The Mount Sinai study does not suggest that risk scores should be discarded entirely. They remain useful for identifying general trends within large populations and public health initiatives. However, the data clearly indicates that for the individual patient sitting in a doctor’s office, these scores are insufficient.
As the medical field continues to grapple with these findings, the conversation is likely to shift toward more personalized, imaging-based approaches to cardiovascular health. By moving the focus from the statistical probability of a heart attack to the physical reality of the plaque within the arteries, physicians may finally be able to close the "prevention gap" and identify patients before they reach a critical and life-threatening event.
The mission, as Dr. Mueller concluded, is clear: "Doctors should shift their focus from detecting symptomatic heart disease to detecting the plaque itself for earlier treatment, which could save lives." As research continues, the integration of advanced imaging into the primary care setting may prove to be the most vital step forward in the war against heart disease.
